Byrne, Christopher D.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,476

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 3,100

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 850

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 844

Current status and future trends of the global burden of MASLD

Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 781

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 674

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 586

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals

Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 481

NAFLD as a driver of chronic kidney disease

Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 449

Maternal High-Fat Feeding Primes Steatohepatitis in Adult Mice Offspring, Involving Mitochondrial Dysfunction and Altered Lipogenesis Gene Expression

Bruce, K. D., Cagampang, F. R., Argenton, M., Zhang, J., Ethirajan, P. L., Burdge, G. C., Bateman, A. C., Clough, G. F., Poston, L., Hanson, M. A., et al. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentBirth, Development, and Health

Cited by 449

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 402

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 397

Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentCancer Risks and Factors

Cited by 363

Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease

Scorletti, E., & Byrne, C. D. (2013) · Annual Review of Nutrition

Fatty Acid Research and HealthLiver Disease Diagnosis and Treatment

Cited by 326

Metabolic Dysfunction–Associated Steatotic Liver Disease

Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 325

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 316

Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease

Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V., & Sookoian, S. (2023) · Journal of Hepatology

Alcohol Consumption and Health EffectsLiver Disease Diagnosis and Treatment

Cited by 307

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentGut microbiota and health

Cited by 237

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review

Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 230

Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents

Mosca, A., Nobili, V., De Vito, R., Crudele, A., Scorletti, E., Villani, A., Alisi, A., & Byrne, C. D. (2017) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 161

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 138

Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals

Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., Bonapace, S., Rossi, A., Tilg, H., Byrne, C. D., & Targher, G. (2023) · Gut

Liver Disease Diagnosis and TreatmentHeart Failure Treatment and Management

Cited by 128

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 121